Research library / NAD+ (NR, NMN)

The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson’s disease

B Brakedal, C Dölle, F Riemer, Y Ma, G Nido, G Skeie et al.. Cell Metabolism. 2022.

Published 2026-10-15Sources checked 2026-10-151 sourceEverstack research teamHow we work

In plain language

NR raised brain NAD and was associated with mild clinical improvement in Parkinson's disease.

Limits

Phase 1; not evidence of treatment.

Source

doi.org/10.1016/j.cmet.2022.02.001 · PubMed 35235774

Summary written by Everstack from the published abstract. Verified against Crossref on 2026-10-15. The authors do not endorse Everstack.